首页> 外文期刊>Biomarkers in Cancer >Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study:
【24h】

Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study:

机译:弥漫性大B细胞淋巴瘤中循环microRNAs作为生物标记物:一项前瞻性的纵向临床研究:

获取原文
获取外文期刊封面目录资料

摘要

Objectives:Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. The aim of this study was to evaluate the use of microRNAs found in plasma from patients with DLBCL as biomarkers of tumor evolution in these patients.Method:For this purpose, a plasma biobank was created with samples from patients with DLBCL. The evolution of the level of selected microRNAs during treatment has been studied. A total of 19 patients with DLBCL were included in this pilot mono-centered study and a total of 68 samples were analyzed.Results:The first step of this study was the selection of the microRNAs to be quantified in all the samples o...
机译:目的:弥漫性大B细胞淋巴瘤(DLBCL)在患者的表型和治疗反应方面高度异质。这些特征使得难以建立预后并且阻碍了在临床实践中使用新的个性化治疗。在这种情况下,当前需要定义新的生物标志物,以更好地定义DLBCL亚型,评估预后并概述对化学疗法的抗性。这项研究的目的是评估使用DLBCL患者血浆中的microRNA作为这些患者肿瘤进化的生物标志物的方法。方法:为此,利用DLBCL患者样品创建了血浆生物库。已经研究了治疗过程中选定的microRNA水平的演变。该试验性单中心研究共纳入19例DLBCL患者,共分析了68个样品。结果:本研究的第一步是在所有样品中选择要定量的microRNA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号